We are in the midst of a revolution in cancer care. Cancer immunotherapies are proving transformational for many patients around the world. By harnessing the power of our own immune systems, we have the potential to fight certain cancers more effectively than ever before. But while use of certain cancer …

Every day at Foundation Medicine, our goal is to help advance the global understanding of cancer in order to transform patient care. We are driven by a commitment to help each person diagnosed with cancer realize the potential benefits of precision medicine; to support physicians in making informed treatment …

–Findings Help Guide Toward Targeted Therapeutic Options, Potentially Improved Outcomes, and Care Efficiencies for Patients and Payers– Foundation Medicine presented data today at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting showing that comprehensive genomic profiling (CGP) with FoundationOne® …

Today, Foundation Medicine and our collaborators presented data at the American Society of Clinical Oncology (ASCO) annual meeting demonstrating that tumor mutational burden (TMB) measured by FoundationOne comprehensive genomic profiling (CGP) is a potentially more sensitive method for identifying responders to …

Cancer immunotherapies are revolutionizing the world of oncology. This exciting new class of medicines retrains the body’s own immune system to fight cancer. Unlike cytotoxic chemotherapy, the immune system is “smart” and can adapt and evolve with the cancer over time – potentially resulting in unprecedented long-term …

The oncology community is gearing up for the largest gathering of the year, the American Society of Clinical Oncology Annual Meeting (ASCO), which will take place June 3-7 in Chicago. The meeting is a critically important annual gathering of thousands of experts where the latest scientific breakthroughs and exciting …

At the White House Precision Medicine Initiative Summit in February, we announced our intention to release genomic profiles of pediatric cancers currently maintained as part of our information knowledgebase, FoundationCORE™. Today, we’re proud to fulfill this commitment and provide the cancer research community with a …

New data published today in The Oncologist by Siraj M. Ali, M.D., Ph.D., our very own associate director, clinical development and medical affairs, along with our collaborators, revealed clinically relevant genomic alterations in penile squamous cell carcinoma (PSCC), a rare cancer for which the oncogenic drivers have …

Here at Foundation Medicine, we’re always excited when we can report important new data that could help improve clinical outcomes for patients. This week, at the American Society of Hematology (ASH) Annual Medical Meeting, we and our collaborators presented exciting new data supporting the use of FoundationOne Heme in …

A new clinical case study published in a research letter in JAMA Oncology shows a beneficial clinical outcome for a patient with a rare tumor type as a result of comprehensive genomic profiling with FoundationOne. The patient, a woman in her 30’s, was diagnosed with an advanced acinic cell tumor of the right parotoid …